Sponsor Deadline
Posted: 4/18/2022

Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)

The purpose of this engineering-oriented funding opportunity announcement (FOA) is to encourage submissions of exploratory/developmental Bioengineering Research Grant (EBRG) applications to demonstrate feasibility and potential utility of new capabilities or improvements in quality, speed, efficacy, operability, costs, and/or accessibility of solutions to problems in basic biomedical, pre-clinical, or clinical research, clinical care delivery, or accessibility.

This FOA runs in parallel with another FOA of identical scientific scope, PAR-22-091, which accepts applications that do or do not propose clinical trial(s).


  • R21 Deadlines: Feb. 16, Jun. 16, Oct. 16

PAR-22-090 Expiration Date: January 8, 2025

Amount Description

The combined budget for direct costs for the two-year project period may not exceed $275,000. No more than $200,000 may be requested in any single year.